Cuộc họp Báo cáo Kết quả Kinh doanh Quý 2/2026 của Journey Medical (DERM): Emrosi Thúc đẩy Doanh thu Tăng trưởng 23%
Cuộc họp công bố kết quả kinh doanh quý 2/2026 của Journey Medical đã ghi nhận mức tăng trưởng doanh thu 23%, lượng đơn thuốc Emrosi tăng tốc, chỉ số EBITDA điều chỉnh đạt mức dương và phạm vi chi trả của các bên thanh toán được cải thiện.
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.